Search for content, post, videos

Positive preclinical results from Spago Nanomedical

Tumorad Emil Aaltonen

Spago Nanomedical has announced new results which show that the company’s candidate drug Tumorad significantly reduces tumor growth and prolongs survival in a preclinical model for colorectal cancer.

Together with previously communicated clinical and preclinical results, the new results provide additional support for the company’s platform technology with nanoparticles for use in several different cancer indications, the company states.

”We are currently evaluating various alternatives to optimize clinical development and the path to the market. With 177Lu-SN201 we have the opportunity to supplement or combine existing standard treatments, and we see interesting possibilities in both larger indications and rarer, so-called orphan indications,” says Mats Hansen, CEO of Spago Nanomedical.

The new results

The new results show that SN201 loaded with the clinically validated isotope lutetium 177 (177Lu) delays tumor growth and prolongs survival by 39% in a preclinical model of colorectal cancer compared to the control group. The results reinforce previous preclinical results with 177Lu-SN201 from a mouse model in aggressive breast cancer. Together with the recently communicated interim results from the company’s ongoing phase 1 study with SpagoPix (SN132D), the results show the strength and breadth of the company’s platform technology.

Clinical trial start in 2022

A first clinical trial with SN201 in humans is planned to start in 2022. Work is underway to produce study protocols and documentation for applications to relevant authorities, as well as identification of suitable hospitals for the study, says the company. In parallel, the production of GMP materials continues at an external contract manufacturer (CMO). The clinical study will be carried out in cancer patients and is designed to document safety of 177Lu-SN201 at different doses, as well as evaluating early proof of concept of its anti-tumor effects.

The project is protected by approved patents in several strategically important regions, including the US, the EU and Japan.

Image: Tumorad. Photo: Emil Aaltonen